| Dr Edwin A Anderson, MD | |
|
1601 Golf Course Rd, Grand Rapids, MN 55744-8648 | |
| (218) 326-5000 | |
| Not Available |
| Full Name | Dr Edwin A Anderson |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 1601 Golf Course Rd, Grand Rapids, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083691828 | NPI | - | NPPES |
| 258013600 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 40223 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Recover Health | Grand rapids, MN | Home health agency |
| Bigfork Valley Hospital | Bigfork, MN | Hospital |
| Grand Itasca Clinic And Hospital | Grand rapids, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cook Area Health Services, Inc | 4880681303 | 26 |
News Archive
The battle against obesity in this country could be tackled one community at a time, according to a newly published study in the Journal of Physical Activity and Health. Researchers at the University of Colorado at Denver demonstrated the effectiveness of changing behaviors at a community level, suggesting that community-based interventions could be a viable option to address the nation's obesity epidemic.
Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.
New research has provided more evidence that an innovative treatment strategy may help prevent brain swelling and death in stroke patients. J. Marc Simard, professor of neurosurgery at the University of Maryland School of Medicine, along with colleagues at Yale University and Massachusetts General Hospital, found that Cirara, an investigational drug, powerfully reduced brain swelling and death in patients who had suffered a type of large stroke called malignant infarction, which normally carries a high mortality rate.
› Verified 4 days ago
| Entity Name | Cook Area Health Services, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174596027 PECOS PAC ID: 4880681303 Enrollment ID: O20040427001470 |
News Archive
The battle against obesity in this country could be tackled one community at a time, according to a newly published study in the Journal of Physical Activity and Health. Researchers at the University of Colorado at Denver demonstrated the effectiveness of changing behaviors at a community level, suggesting that community-based interventions could be a viable option to address the nation's obesity epidemic.
Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.
New research has provided more evidence that an innovative treatment strategy may help prevent brain swelling and death in stroke patients. J. Marc Simard, professor of neurosurgery at the University of Maryland School of Medicine, along with colleagues at Yale University and Massachusetts General Hospital, found that Cirara, an investigational drug, powerfully reduced brain swelling and death in patients who had suffered a type of large stroke called malignant infarction, which normally carries a high mortality rate.
› Verified 4 days ago
| Entity Name | Cook Area Health Services, Inc |
|---|---|
| Entity Type | Part A Provider - Federally Qualified Health Center (fqhc) |
| Entity Identifiers | NPI Number: 1437124401 PECOS PAC ID: 4880681303 Enrollment ID: O20040707000064 |
News Archive
The battle against obesity in this country could be tackled one community at a time, according to a newly published study in the Journal of Physical Activity and Health. Researchers at the University of Colorado at Denver demonstrated the effectiveness of changing behaviors at a community level, suggesting that community-based interventions could be a viable option to address the nation's obesity epidemic.
Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.
New research has provided more evidence that an innovative treatment strategy may help prevent brain swelling and death in stroke patients. J. Marc Simard, professor of neurosurgery at the University of Maryland School of Medicine, along with colleagues at Yale University and Massachusetts General Hospital, found that Cirara, an investigational drug, powerfully reduced brain swelling and death in patients who had suffered a type of large stroke called malignant infarction, which normally carries a high mortality rate.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edwin A Anderson, MD 1601 Golf Course Rd, Grand Rapids, MN 55744-8648 Ph: (218) 326-5000 | Dr Edwin A Anderson, MD 1601 Golf Course Rd, Grand Rapids, MN 55744-8648 Ph: (218) 326-5000 |
News Archive
The battle against obesity in this country could be tackled one community at a time, according to a newly published study in the Journal of Physical Activity and Health. Researchers at the University of Colorado at Denver demonstrated the effectiveness of changing behaviors at a community level, suggesting that community-based interventions could be a viable option to address the nation's obesity epidemic.
Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.
A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.
New research has provided more evidence that an innovative treatment strategy may help prevent brain swelling and death in stroke patients. J. Marc Simard, professor of neurosurgery at the University of Maryland School of Medicine, along with colleagues at Yale University and Massachusetts General Hospital, found that Cirara, an investigational drug, powerfully reduced brain swelling and death in patients who had suffered a type of large stroke called malignant infarction, which normally carries a high mortality rate.
› Verified 4 days ago
Dr. Patricia C. Carlin-janssen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Golf Course Rd, Grand Rapids, MN 55744 Phone: 218-326-5000 | |
Anne Eileen Tofte, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Golf Course Rd, Grand Rapids, MN 55744 Phone: 218-326-5000 | |
Kristin A Johnson, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 409 Se 13th St, Grand Rapids, MN 55744 Phone: 218-326-9100 Fax: 218-326-9200 | |
Dr. Timothy J. Pehl, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Golf Course Rd, Grand Rapids, MN 55744 Phone: 218-326-5000 | |
Dr. Michael B. Liebe, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Golf Course Rd, Grand Rapids, MN 55744 Phone: 218-326-5000 | |
Arie Degrio, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Golf Course Rd, Grand Rapids, MN 55744 Phone: 218-999-1442 Fax: 218-999-1461 |